UBS Group Initiates Coverage on Celldex Therapeutics (NASDAQ:CLDX)

Research analysts at UBS Group started coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report issued on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $44.00 price target on the biopharmaceutical company’s stock. UBS Group’s price target suggests a potential upside of 97.66% from the stock’s current price.

Several other analysts also recently issued reports on CLDX. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.22.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $22.26 on Thursday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -8.66 and a beta of 1.60. Celldex Therapeutics has a fifty-two week low of $20.91 and a fifty-two week high of $53.18. The stock’s fifty day moving average is $24.93 and its two-hundred day moving average is $30.08.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its position in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares in the last quarter. KBC Group NV lifted its stake in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics in the fourth quarter worth about $81,000. AlphaQuest LLC grew its stake in shares of Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,705 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in Celldex Therapeutics in the 4th quarter worth approximately $273,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.